Alyeska Investment Group
REGN icon

Alyeska Investment Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Alyeska Investment Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-40,000
Closed -$16.4M – 567
2014
Q4 		$16.4M Buy
+40,000
New +$15.7M 0.28% 130

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Alyeska Investment Group's REGN Position: Q2 2024 in Review

Alyeska Investment Group sold out of Regeneron Pharmaceuticals (REGN) in Q2 2024, closing a stake of 41,476 shares — an estimated $39.9M sold.

Alyeska Investment Group first reported a position in REGN in Q2 2013 and held it in 8 quarters. The position peaked at $80.6M in Q2 2023. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2024.

  • Alyeska Investment Group reported no remaining Regeneron Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Alyeska Investment Group sold 41,476 Regeneron Pharmaceuticals shares in Q2 2024, an estimated $39.9M.
  • Alyeska Investment Group first reported a position in Regeneron Pharmaceuticals in Q2 2013 and held it in 8 quarters.
  • Alyeska Investment Group's Regeneron Pharmaceuticals position peaked at $80.6M in Q2 2023.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2024.

Based on Alyeska Investment Group's 13F filing for Q2 2024, filed 14 Aug 2024.